期刊
CANCER INVESTIGATION
卷 26, 期 1, 页码 81-95出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/07357900701511847
关键词
-
类别
Expression of epidermal growth factor and its transmembrane receptor (EGFR) stimulates tumor growth. Matuzumab is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth, and provides a clinical benefit for some patients. The plasma half-life (6-10 days) and pharmacodynamic activity allow flexible dosing on weekly, every-2-week, and every-3-week schedules. Matuzumab has shown single-agent antitumor activity in heavily pretreated patients with a variety of tumors, with a favorable safety profile. Skin rash is the most common toxicity, but is severe (Grade 3) in < 1 percent. This article describes preclinical and clinical development of matuzumab.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据